Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
Lau
Derick
D
University of California, Davis Cancer Center and Veteran Administration Northern California Health System, Sacramento, CA, USA. derick.lau@ucdmc.ucdavis.edu
Guo
Linlang
L
Gandara
David
D
Young
Lawrence J T
LJ
Xue
Ling
L
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D005260:Female; D006131:Growth Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D020533:Angiogenesis Inhibitors; D006131:Growth Inhibitors; D017239:Paclitaxel